title: [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
abstract: We have investigated the efficacy of intraperitoneal or intrathoracic administration of hydroxyapatite particles (HAp) loaded carboplatin (CBDCA). HAp-CBDCA (HAp; 200 mg, CBDCA; 4 mg) was administered intraperitoneally to rats with peritoneal carcinomatosis. The area under the curve of the ascitic platinum (Pt) increased significantly with rats given HAp-CBDCA, and the omental Pt levels in the HAp-CBDCA group remained higher and longer. Additionally, the HAp-CBDCA group showed a trend toward longer survival when compared with the CBDCA alone group. In clinical use, HAp-CBDCA (HAp; 5 g, CBDCA; 150 mg) was administered intrathoracically to a patient who had undergone esophagectomy. The Pt in serum was detected until 7 days after administration of HAp-CBDCA.
authors.affiliation: First Dept. of Surgery, Nagoya City University, Medical School.
authors.forename: N
authors.initials: N
authors.lastname: Mohri
authors.forename: I
authors.initials: I
authors.lastname: Mizuno
authors.forename: Y
authors.initials: Y
authors.lastname: Akamo
authors.forename: H
authors.initials: H
authors.lastname: Takeyama
authors.forename: T
authors.initials: T
authors.lastname: Manabe
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D006801:Humans; D006882:Hydroxyapatites / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007263:Infusions, Parenteral; D008297:Male; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D013909:Thorax
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D006882:Hydroxyapatites; D016190:Carboplatin